Solventum Co. (NYSE:SOLV) Shares Acquired by Savant Capital LLC

Savant Capital LLC increased its stake in shares of Solventum Co. (NYSE:SOLV) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,914 shares of the company’s stock after buying an additional 233 shares during the quarter. Savant Capital LLC’s holdings in Solventum were worth $259,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC bought a new stake in shares of Solventum during the third quarter valued at approximately $60,000. Blue Trust Inc. acquired a new position in Solventum during the 3rd quarter worth $538,000. Copeland Capital Management LLC bought a new position in shares of Solventum in the third quarter worth $26,000. Foundations Investment Advisors LLC acquired a new stake in Solventum in the third quarter worth about $345,000. Finally, Sequoia Financial Advisors LLC increased its stake in Solventum by 8.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 5,737 shares of the company’s stock valued at $400,000 after buying an additional 441 shares during the period.

Solventum Trading Up 0.0 %

SOLV opened at $74.27 on Wednesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The stock has a fifty day moving average of $70.82 and a 200-day moving average of $68.76.

Analyst Ratings Changes

Several research analysts recently weighed in on SOLV shares. Piper Sandler raised their target price on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Mizuho began coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective on the stock. Finally, Morgan Stanley raised their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Solventum has a consensus rating of “Hold” and a consensus target price of $68.29.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.